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Tumor-suppressor geneEpigenetic changes of genomic DNA are involved in the development and progression of many cancers. Aberrant
methylation of CpG islands in the promoter regions of certain tumor-suppressor genes (TSG) is frequently
observed in cancer cells. Protocadherin 10 (PCDH10), a member of the cadherin superfamily, is a recently
identiﬁed putative TSG. PCDH10 is frequently silenced in many solid tumors. However, the role of
PCDH10 in gastric cancer is largely unknown. In this study, we examined the expression and methylation
status of PCDH10 in gastric cancer cells and tissues by real time PCR and methylation-speciﬁc PCR (MSP),
and then investigated the biological function of PCDH10. We found that the expression of PCDH10 was
markedly reduced in gastric cancer cells and tissues. The reduced expression correlated with hypermethy-
lation of this gene in its promoter region, as demonstrated by MSP and bisulﬁte genomic sequencing (BGS)
analysis. In addition, pharmacological demethylation using 5-Aza restored the expression of PCDH10 in gastric
cancer cells. Over-expression of PCDH10 in gastric cancer cells suppressed cell proliferation and migration, but
did not cause marked apoptosis. Over-expression of PCDH10 also suppressed growth of xenograft tumors in
nude mice. Thus, PCDH10 functions as a TSG in gastric cancer, and might be a useful target for cancer therapy.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer (GC) is the fourth most common malignancy
worldwide [1]. Genetic and epigenetic changes of genomic DNA are
involved in the development and progression of many cancers
[2–4]. Aberrant methylation of CpG islands in the promoter regions of
certain tumor-suppressor genes (TSGs) is regarded as one of the earliest
and most frequent alterations in cancer cells. Such a phenomenon (so
called tumor-speciﬁc promoter methylation) may serve as a marker
for cancer diagnosis and prognosis [5,6]. Thus, aberrant methylation of
CpG islands in 5′ regions of genes is a promising candidate for tumor
biomarkers [7]. The development of GC and its metastasis have
been closely linked to the epigenetic alterations of certain TSGs
such as cadherins [8,9].bisulﬁte genomic sequencing;
C, gastric cancer; MSP, methyl-
rin 10; PCR, polymerase chain
ain reaction; TSG, tumor-sup-
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l rights reserved.Cadherins are transmembrane glycoproteins of a large superfamily
that includes the classic cadherins, desmosomal cadherins, protocad-
herins, atypical cadherins, and cadherin-related neuronal receptors
[10–12]. At least 80 members of the cadherin superfamily have
been identiﬁed in mammals. Classic cadherins play important roles
in the calcium-dependent homophilic cell–cell adhesion [13,14].
These molecules are also involved in the establishment of cell polarity,
cell-sorting, cell proliferation, migration, and differentiation.
The protocadherin gene subfamily consists of more than 60 member
genes, many of them are thought to be highly speciﬁc to nervous tissue
[15]. Protocadherin 10 (PCDH10, also termed OL-PCDH or KIAA1400), a
member of the protocadherin gene subfamily, is a recently identiﬁed pu-
tative tumor-suppressor gene localized at chromosome 4q22.2 [11,16].
PCDH10 is richly expressed in the central nervous system (CNS)
and is important for the development and functioning of CNS
[17,18]. It is also expressed in testis and ovary but is expressed at a
low level in other tissues. Recent studies have showed that PCDH10
is down-regulated and hypermethylated in many human cancers in-
cluding breast cancer, nasopharyngeal cancer, esophageal cancer, and
some haematologic malignancies [4,19,20]. In addition, forced over-
expression of PCDH10 was able to suppress the growth of several
human cancers including nasopharyngeal, esophageal cancer, and
colon cancer cells [20]. Thus, PCDH10 may be a potential target gene
for cancer gene therapy. However, the precise association between
PCDH10 and the pathogenesis of GC remains unclear.
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GC cells and tissues, as well as its methylation status. The ultimate
goal of this study is to determine whether PCDH10 can be used as a
potential target gene for GC therapy.
2. Materials and methods
2.1. Chemicals, antibodies, assay kits
Antibody against human PCDH10 was purchased from Abnova
(Taipei, Taiwan). CpG genome DNA Modiﬁcation Kit was purchased
from Chemicon (Temecula, CA). Lipofectamine 2000 was purchased
from Invitrogen (Carlsbad, CA, USA). Dual-Luciferase Reporter Assay
System was purchased from Promega (USA). 5-Aza-2′-deoxycytidine
(5-Aza) and other common chemicals were purchased from Sigma
Chemical Co. (St. Louis, MO, USA), unless otherwise stated.
2.2. GC cell lines and primary GC tissues
NCI-N87, SNU-1, and AGS were purchased from American Type
Culture Collection (ATCC, Rockville, MD, USA), TMK-1, MNK74, and
MNK7 were purchased from the Cell Resource Bank (Ibaraki, Japan),
and BCG7901 were a gift from Beijing Cancer Institute, China. All
cell lines were cultured in RPMI medium 1640 (GIBCO/BRL) supple-
mented with 10% fetal bovine serum (FBS), maintained at 37 °C in
an atmosphere of 5% CO2. CpGnome universal methylated DNA as pos-
itive control of methylation and the DNA samples as negative control
were described previously [21]. Twelve pairs of primary GC tissues
and matched non-cancerous gastric tissues were obtained from pa-
tients who underwent surgery with moderate to poorly differentiated
gastric adenocarcinoma. None of the patients had received preoperative
chemotherapy. Samples obtained from surgical operations were either
immediately ﬁxed in 10% neutral formalin for histology and immuno-
histochemistry, or snap frozen in liquid nitrogen and stored at−80 °C
for further PCR and Western blot analysis. Written consents from the
tissue donor patients were obtained and the study was approved by
the relevant ethics committees.MNK7 MNK74 7901 N87 SN
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Fig. 1. Expression of PCDH10 was detected in GC cell lines (A, B) and gastric tissues (C, D) by
as an internal control for both PCR and Western blot. The quantitative data from immunohis
the GC tissues compared to normal gastric tissues (C, D).2.3. RNA isolation and reverse transcription polymerase chain reaction
(RT-PCR)
Total RNA was isolated from GC cells or tissues using Trizol re-
agent (Invitrogen Corp., Carlsbad, California, USA). One microgram
RNA was reverse transcribed with SuperscriptII reverse transcriptase
(Invitrogen, USA) to generate the single-stranded cDNAs. RT-PCR was
performed as described [22]. The primers used are as follows. PCDH10
(forward): 5′-TGTCCTTCATCTTCCTGCTGG-3′, PCDH10 (reverse): 5′-
AGGCTGCTGGTCGGTGTAAC-3′. GAPDH was used as internal control
with the speciﬁc primers as follows. GAPDH (forward): 5′-GTCAACG-
GATTTGGTCGTATTG-3′, GAPDH (reverse): 5′-CTCCTGGAAGATGGT-
GATGGG-3′.
2.4. Isolation of genomic DNA, bisulﬁte modiﬁcation, methylation-
speciﬁc PCR (MSP), and bisulﬁte genomic sequencing (BGS) analysis
Genomic DNA was isolated from cell lines and tissues by DNeasy
Tissue Kit (Qiagen, Valencia, CA USA). Bisulﬁte modiﬁcation was per-
formed to convert unmethylated cytosine to uracil, as our group de-
scribed [21]. The genomic DNA samples used as positive (M) and
negative (U) controls were CpGenome Universal Methylated DNA and
CpGenome Universal Unmethylated DNA (Chemicon), respectively.
Primers were designed using MethPrimer (http://itsa.ucsf.edu/urolab/
MethPrimer). MSP1 primers are located far from the transcript start
site and core promoter, and MSP2 primers are near the transcript start
site and core promoter. Detailed sequences of the primer sets are as fol-
lows. M-MSP1 (Forward), GTTAGGGAGGATGGATGTAAGTATC (−2030
to −2006); M-MSP1 (Reverse), GCGAAATAAAAACAATAAAACGAC
(−1909 to −1886); U-MSP1 (Forward), GTTAGGGAGGATGGATG-
TAAGTATT (−2030 to −2006); U-MSP1 (Reverse), CCCACAAAA-
TAAAAACAATAAAACAA (−1908 to −1883); M-MSP2 (Forward),
AGTTATAGGAGTTTTTACGTAGCGT (−112 to−88); M-MSP2 (Reverse),
ATATTCCTACTCCTCCTATACCGTA (+76 to +90); U-MSP2 (Forward),
GAAAGTTATAGGAGTTTTTATGTAGTGT (−115 to −86); U-MSP2 (Re-
verse), ATATTCCTACTCCTCCTATACCATA (+66 to +90). (M: methylat-
ed, U: unmethylated). For BGS, PCR products were puriﬁed and then
inserted into pGEM-T (Promega, Madison, WI) vector. Around eight toGAPDH
PCDH10
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Fig. 2. Expression of PCDH10 by immunohistochemistry. A, negative control; B, normal gastric mucosa, low magniﬁcation (×100); C: normal gastric mucosa, high magniﬁcation
(×400), D: gastric cancer tissue (×100).
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to determine the methylation status of each CpG site. The primers used
for BGS are as follows: BGS (Forward): GGAAGAAAATAGTAGAAAA-
GAAATTGTTTATTA (−752− to−720), GS (Reverse): CCTATAACTTTC-
TATCTTTAAAAATCTTACTCC (−152 to−120).
2.5. Immunohistochemistry
The expression of PCDH10 was detected by immunohistochemistry
with anti-human PCDH10. The immunostaining results were scored
semi-quantitatively using a product score of percentage positive cells
times staining intensity in at least 5 microscopic ﬁelds at ×400
magniﬁcation.
2.6. Promoter constructs
Detailed procedures were previously reported [21]. Brieﬂy, ﬁve insert
DNA fragments of the 5′-ﬂanking region of the PCDH10 gene include PA
(located −2198/−1835nt upstream of the ATG start codon), PB
(−1846/−1597nt), PC (−1572/−1304 nt), PD (−1277/−816 nt),
and PE (−231/−30 nt) were ampliﬁed by PCR. The ampliﬁed DNA frag-
mentswere inserted into a ﬁreﬂy luciferase expression vector pGL3-basic
plasmid (Promega), to generate the reporter constructs pGL3-PA, pGL3-
PB, pGL3-PC, pGL3-PD, and pGL3-PE. The empty pGL3 basic plasmid
was used as a control. The accuracy of each plasmid construct was con-
ﬁrmed by subcloning them into DH5α competent cells followed by
restriction enzyme digestion and sequence analysis (ABI PRISM Big
Dye Terminator Cycle Sequencing Kit, Applied Biosystems, CA).2.7. Transient transfection, in vitro methylation, and luciferase reporter
assay
Three GC cell lines MKN74, 7901 and AGS were transfected with
pGL3-PA, pGL3-PB, pGL3-PC, pGL3-PD, pGL3-PE, or pGL3-basic plasmid
(0.8 μg/well) by Lipofectamine 2000. Luciferase activitywas determined
in cell lysate after 24 h using a Dual-Luciferase Reporter Assay System
and normalized with respect to Renilla luciferase activity. Relative pro-
moter activity was expressed by comparing those of the pGL3-basic
plasmid. Each experiment was performed in triplicate, and at least 3
sets of independent experiments were performed. Luciferase activity
was reported as the mean of 3 independent transfection experiments.
For in vitro methylation assay on the promoter fragment PD of
PCDH10 gene, we used SssI methylase, as reported previously [21].
To over-express PCDH10 in GC cells, we constructed the plasmid
containing the full-length coding region of PCDH10 using pcDNA3.2/
V5-DEST vector. The plasmid sequenceswere conﬁrmed by sequencing.
Stable transfection with PCDH10 and selection of positive clones with
Geneticin were performed as we previously described [21,22].
2.8. Cell proliferation assays and Western blot analysis
Cell proliferation was determined by a WST-1 assay as described
previously [22–25]. Cell growth was also examined by trypan blue ex-
clusion assay. The experiments were performed for three times. The
protein expression of caspase, cIAP1, cIAP2, XIAP, and PCDH10 was
examined by Western blot analysis using the respective speciﬁc
antibodies.
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To generate the xenograft tumors in mice, stable AGS cells were
cultured and harvested at the exponential phase. Approximately
1×107 cells were resuspended in 100 μl of sterile PBS, inoculated subcu-
taneously into the right dorsalﬂankofmale BALB/c-nu/numice. Sixmice
were used for each group. Tumor volume and body weight of the mice
were monitored, as we previously reported [22–23]. Apoptosis in the
tumor tissues was detected by TUNEL assay as described in our previous
publication [23]. The animal study was approved by the Committee on
the Use of Live Animals in Teaching and Research of the University of
Hong Kong.
2.10. Statistical analysis
The quantitative results were expressed as mean±SD. Student t test
was used to determine the statistical signiﬁcance between different
groups. A p value of less than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Expression of PCDH10 in GC cell lines and gastric tissues
We examined the expression of the PCDH10 in seven human GC
cell lines. The expression level of PCDH10 was detected by RT-PCR
and Western blot. As shown in Fig. 1, PCDH10 was undetectable inM U
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Fig. 3. Schematic structure of the PCDH10 gene and CpG islands, and methylation status of P
angles. Exons are indicated by a black rectangle. The translation start site is indicated by a
representative results of MSP assay in seven GC cell lines (B) and ﬁve pairs of gastric tissueﬁve out of seven cell lines at the mRNA (Fig. 1A) and six out of
seven cell lines at protein levels (Fig. 1B). Among the cell lines tested,
PCDH10 mRNA was detectable in N877 and 7901 cells. At the protein
level, the expression of PCDH10was barely visible in all cell lines except
in N87 cells. In separate Western blot experiments, the expression of
PCDH10 was visible at a very low level in MNK74, 7901, and AGS cells
(Fig. 7A, B).
We then examined the expression of PCDH10 in twelve pairs of GC
tissues andmatched non-cancerous tissues. By immunohistochemistry,
PCDH10 was expressed at a reduced level in GC tissues compared to
matched normal gastric tissues (Fig. 1C). Overall, PCDH10 is expressed
at a reduced level in more than 86% of GC tissues compared to their
matched non-cancerous gastric tissues (D). Typical immunostaining
photos are shown in Fig. 2 which shows that normal gastric mucosa ex-
presses higher level of PCDH10 (B) than gastric cancer tissues (D). At
higher power, PCDH10was found to be present largely in the cytoplasm
of the glandular cells and stromal cells (B). The speciﬁcity of the
immunostaining was veriﬁed by the negative control (A).
3.2. Methylation status of PCDH10 in GC cells and tissues
We scanned PCDH10 genomic DNA sequence using a free software
(26) and found that Exon 1 and Exon 5 of the PCDH10 gene are
enriched with CpG dinucleotides (Fig. 3A). We then designed MSP
primers to detect themethylation status of these CpG islands.Methylated
alleles were present on CpG islands on the PCDH10 promoter regionNormal
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designated these islands PA, PB, PC, PD, and PE (Fig. 3A). Methylation of
PCDH10promoterwasmore frequently observed inGC tissues compared
to paired non-cancerous tissues (Fig. 3C). The MSP results were further
veriﬁed by bisulﬁte genomic sequencing (BGS), which was performed
on the region of PCDH10 promoter CpG islands. By this assay, extensive
hypermethylation at CpG sites in all seven human GC cell lines was ob-
served (Fig. 4A). More than 88% of the tested islands from the seven cell
lines contain heavily hypermethylated alleles (80–100% methylation).
Similarly, majority of GC tissues harbor heavy methylation (Fig. 4A).
3.3. Restoration of PCDH10 expression by treatment with 5-Aza
To test whether methylation directly mediates PCDH10 silencing,
we treated several GC cell lines in which PCDH10 is heavily methylated
and silenced with 5-Aza, a commonly used demethylating agent. As
shown in Fig. 4B, treatment of cells with 5 μM 5-Aza for 72 h restored
PCDH10 mRNA expression in all three cell lines (MNK74, 7901, and
AGS). This restoration was also observed at the protein level (Fig. 4C).
In addition, by MSP assay, treatment of these three cell lines with 5-
Aza led to the reappearance of unmethylated PCDH10 alleles (Fig. 4D).
By BGS, most of the methylated CpG sites of PCDH10 promoter were
demethylated or partially demethylated by 5-Aza in three cell lines
(Fig. 4E). These results indicate that methylation directly mediates the
transcriptional silencing of PCDH10 in GC.
3.4. PCDH10 promoter activity
As described above, by BGS, promoter region and Exon 1 of the
PCDH10 gene were enriched with CpG dinucleotides (Fig. 3A). We
identiﬁed ﬁve CpG islands (PA, PB, PC, PD, and PE). By computer scan-
ning, fragment PD contains Sp1 consensus sequence (GGTGGG) in the
region proximal to the translation start site. As described in the above
section, these fragments were cloned and inserted into the pGL3* #
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were transfected with pcDNA3.2 (control) or pcDNA3.2-PCDH10 (PCDH10) for 48 h and the
the migration was determined by a wound healing assay in AGS cells transfected with contLuciferase Report Assay vectors. We transfected MNK74, 7901 and
AGS cells with these constructs, and the activities of these promoter
constructs were tested by standard luciferase assay. As shown in
Fig. 5A, most signiﬁcant promoter activity was found in the fragment
PD. We then performed an in vitromethylation assay on the promoter
fragment PD using SssI methylase. MNK74, 7901 and AGS cells were
transfected with unmethylated PD fragment (pGL-PD) or methylated
PD fragment (pGL-PDSss1), and the luciferase activity was measured.
As shown in Fig. 5B, the luciferase activity of pGL-PDSss1 was very
much reduced, further conﬁrming that the promoter activity of the
PCDH10 is located on the fragment D (PD), and the promoter methyla-
tion was responsible for their gene silencing.
3.5. Ectopic expression of PCDH10 inhibited GC cells proliferation
The above results suggested that PCDH10 functions as a tumor-
suppressor gene, and promoter methylation was responsible for its si-
lencing in GC. We thus investigated the effect of ectopic expression of
PCDH10 on human GC cells. We constructed PCDH10 over-expressing
plasmidusingpcDNA3.2 vector.MNK74, 7901 andAGS cellswere stably
transfected with empty pcDNA3.2 (control) or pcDNA3.2-PCDH10
(PCDH10), and cell proliferation was assessed by WST-1 assay. As
shown in Fig. 6A, over-expression of PCDH10 in these cell lines resulted
in a signiﬁcant time-dependent inhibition of cell proliferation. Similar
results were also obtained by trypan blue exclusion assay, which
showed that over-expression of PCDH10 for 48 h led to a reduced cell
growth in MNK74, 7901 and AGS cells (Fig. 6A). We then examined
the effect of PCDH10 over-expression on cell migration. The wound of
the monolayer transfected with pcDNA3.2 (control) was completely
healed by 72 h after scratch injury (Fig. 6E). In contrast, the healing pro-
cess of thewoundof themonolayer transfectedwith pcDNA3.2-PCDH10
(PCDH10)wasmarkedly inhibited (Fig. 6F).We also examined the effect
of PCDH10 on apoptosis-related proteins. Transfection of AGS cells with
PCDH10 did not cause amarked increase in apoptosis (data not shown).D
F
detected by WST-1 assay in MNK74, 7901, and AGS cells (A) following transfection with
ethod, trypan blue exclusion was also used to measure the growth of these cells. Cells
viable cell numbers was counted by trypan blue exclusion (B). The effect of PCDH10 on
rol (C, E) or PCDH10 (D, F) at 0 (C, D) and 48 h (E, F). *: pb0.05; #: pb0.01.
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caused a mild decrease in pro-caspases 3 and 8, but no obvious changes
in pro-caspases 9 and 7 (Fig. 7B). Over-expression of PCDH10 was also
found to reduce the expression of cIAP2, but only marginally affected
the expressions of cIAP1 and XIAP (Fig. 7B). Similar results were found
in other gastric cancer cells including MNK45, NCI87, and TMK1 cells
(Data not shown).
3.6. Effect of PCDH10 on the xenograft tumor growth in nude mice
We ﬁrst generated stable cell lines over-expressing PCDH10 in
MNK74, 7901, and AGS. As shown in Fig. 7A, all three stable cell lines
expressed markedly enhanced expression of PCDH10. To generate the
xenograft tumors, stable AGS cells were injected subcutaneously in
nude mice. All animals developed visible tumors by day 5. There was
notmuch difference in the tumorigenecity between AGS cells tranfected
with pcDNA3.2 (Control) and cells transfected with pcDNA3.2-PCDH10
(PCDH10) before day 14. Thereafter, the tumors grew at a much slower
speed in the PCDH10 group compared to those in the control group. By
18 and 25 days after tumor cell inoculation, the average tumor volume
in the PCDH10 group was signiﬁcantly lower than that in the control
group (Fig. 7C). No difference in apoptosis of the xenograft tumor tissues
were found between the two groups (data not shown).
4. Discussion
In this study, we ﬁrst demonstrated that PCDH10 is silenced in GC
cell lines and tissues. Overall, reduced expression of PCDH10 wasCon PCDH10
PCDH10
Transfection
Caspase 3
Caspase 7
Caspase 8
Caspase 9
cIAP1
cIAP2
XIAP
GAPDH
A
B
Con PCDH10
MNK7
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7901
Fig. 7. Effect of PCDH10 on apoptosis-related protein of GC cells and xenograft tumor grow
Stable AGS cells were cultured for 48 h, and cells were harvested, lyzed, and processed for W
Effects of PCDH10 on the growth of xenograft GC were examined in nude mice. Mice were s
PCDH10 (PCDH10, n=6). Tumor growth velocity was monitored. Tumor volume was measobserved in around 80% of GC cell lines analyzed. An even higher rate
of methylation was recently reported [26]. We also measured the ex-
pression of PCDH10 in 12 pairs of human GC tissues and their corre-
sponding non-cancerous gastric tissues, and found that as many as
86% of tumor tissues had reduced expression compared with their
paired non-tumor tissues.
Genetic and epigenetic alterations of the TSGs leading to a loss of
function are important mechanisms involved in tumor development
and progression [3]. In particular, hypermethylation of the CpG
islands of the TSGs is a frequently observed phenomenon in the geno-
mic DNA of many solid tumors. In our study, we found that majority of
the promoter CpG islands of PCDH10 gene were heavily methylated, as
indicated by the abundant presence of hypermethylated alleles in the
CpG islands of the promoter areas of PCDH 10 gene in GC cells and tis-
sues. Thus, the current study indicates that the reduced expression of
PCDH10 inGCmaybe adirect result of hypermethylation of the genepro-
moter. This statement is further supported by our demethylation study:
5-Aza treatment signiﬁcantly up-regulated the expression of PCDH10.
It was reported that 42% of GC tissues have hypermethylation in
the promoter region of PCDH10 gene [20]. Our results indicate an
even higher rate of hypermethylation: 86% of GC tissues and all GC
cell lines contain hypermethylated alleles of the PCDH10 gene.
These results enriched the current literature by addingmore informa-
tion that PCDH10 is frequently silenced as a result of hypermethylation at
the promoter region. As it is currently believed, hypermethylation of the
promoter regions of some TSGs are among the importantmechanisms of
cancer development [2–4]. Based on previous studies by others and our
current results, we believe PCDH10 may be a novel TSG in GC.7 14 18 25
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305Z. Li et al. / Biochimica et Biophysica Acta 1823 (2012) 298–305We therefore performed functional studies in several GC cell lines
to unveil the biological function of PCDH10. We found that exogenous
expression of PCDH10 strongly suppressed their proliferation and mi-
gration. Preliminary results from the in vivo studies in nude mice have
indicated that PCDH10 suppressed the growth of xenograft tumors.
The inhibitory effect of PCDH10 on the xenograft tumors may be attrib-
utable to the anti-proliferative effect of PCDH10. In our study, by using
several complimentary apoptosis assays, we did not reveal a pro-
apoptotic effect of PCDH10. Thus, apoptosis may not be a major mecha-
nism responsible for the tumor suppression in nude mice. The observed
effect of PCDH10 over-expression on apoptosis in gastric cancer cells
was somewhat different from what has been recently reported that
PCDH10 possesses strong apoptotic effect in gastric cancer MKN45
cells [26]. One potential reason for this discrepancy may derive from
the fact that apoptosis was detected by different methods in these two
studies. It is generally believed that a reliable detection of apoptosis, es-
pecially early apoptosis cannot be achieved by identifying sub-G1 peak
in a cell cycle analysis using PI staining. Based on our study, we believe
that PCDH10 does not hold pro-apoptotic but anti-proliferative effect
in gastric cancer cells. More investigations are needed to further clarify
the role of PCDH10 in regulating apoptosis in gastric cancer.
It is worth mentioning, that on the promoter region of PCDH10
gene, there are binding sites for SP1, indicating that the expression
and function of PCDH10 might be regulated by these transcription
factors. Further studies are required to characterize how PCDH10 is
regulated in cancers.
In summary, PCDH10 is silenced in GC cells and cancer tissues due to
hypermethylation in the promoter region of this gene. Demethylation
of PCDH10 promoter by 5-Aza could restore the expression of
PCDH10. Over-expression of PCDH10 was able to suppress the growth
in vitro and in vivo. More studies are warranted to further clarify how
PCDH10 functions as a TSG in GC.
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